PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer
November 28 2023 - 7:30AM
PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the
“Company”), a clinical-stage immunotherapy company developing a
growing pipeline of targeted cancer immunotherapies and infectious
disease vaccines based on the Company’s proprietary T cell
activating platforms, today announced the appointment of Lars
Boesgaard as Chief Financial Officer (CFO), effective as of
December 4, 2023. Mr. Boesgaard succeeds Matthew Hill, who resigned
as PDS Biotech’s CFO on November 21, 2023, effective December 1,
2023, to pursue other professional endeavors.
“We are delighted to welcome Lars to the PDS
Biotech team. He is an experienced CFO with an impressive track
record of guiding biotech companies to create strategic growth. I
look forward to his insights as well as his financial expertise and
oversight as we continue to mature our business and advance our
lead targeted cancer immunotherapy clinical candidates towards
commercialization,” said Frank Bedu-Addo, PhD, President and Chief
Executive Officer of PDS Biotech. “Additionally, we would like to
thank Matt for his contributions to PDS Biotech’s progress and wish
him all the best in his new role.”
Mr. Boesgaard has had a career spanning more
than 25 years in healthcare and has deep capital markets and
investor relations experience with global clinical and
commercial-stage pharmaceutical and biotechnology companies. He has
prepared and executed corporate transactions and built financial
frameworks for rapidly growing organizations. Prior to joining PDS
Biotech, Mr. Boesgaard served as CFO of AM-Pharma B.V. from
September 2021 to August 2023. Mr. Boesgaard also served as CFO of
Columbia Care from August 2018 to August 2021, where he completed
key transactions including an IPO / reverse merger resulting in a
$120 million capital infusion and raising $200 million in public
equity and debt offerings. Mr. Boesgaard was also previously the
Vice President, CFO of Roka Bioscience from November 2015 to July
2018 and held several other senior finance positions with publicly
traded companies including Insulet Corporation, Alexion
Pharmaceuticals and Novo Nordisk A/S. Mr. Boesgaard holds a
Bachelor of Science in Business Administration from the Copenhagen
Business School and a Master of Business Administration from the
Richard Ivey School of Business, Western University, Ontario,
Canada.
“I’m excited to join PDS Biotech as the company
advances its robust pipeline of groundbreaking targeted cancer
immunotherapies,” said Mr. Boesgaard. “I look forward to working
with the team to help drive PDS Biotech’s business strategy and
financial growth.”
About PDS BiotechnologyPDS
Biotech is a clinical-stage immunotherapy company developing a
growing pipeline of targeted cancer and infectious disease
immunotherapies based on our proprietary Versamune®, Versamune®
plus PDS01ADC, and Infectimune® T cell-activating platforms. We
believe our targeted immunotherapies have the potential to overcome
the limitations of current immunotherapy approaches through the
activation of the right type, quantity and potency of T cells. To
date, our lead Versamune® clinical candidate, PDS0101, has
demonstrated the ability to reduce and shrink tumors and stabilize
disease in combination with approved and investigational
therapeutics in patients with a broad range of HPV16-associated
cancers in multiple Phase 2 clinical trials and plan to advance
into a Phase 3 clinical trial in combination with KEYTRUDA® for the
treatment of recurrent/metastatic HPV16-positive head and neck
cancer in the first quarter 2024. Our Infectimune® based vaccines
have also demonstrated the potential to induce not only robust and
durable neutralizing antibody responses, but also powerful T cell
responses, including long-lasting memory T cell responses in
pre-clinical studies to date. To learn more, please visit
www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
Forward Looking StatementsThis
communication contains forward-looking statements (including within
the meaning of Section 21E of the United States Securities Exchange
Act of 1934, as amended, and Section 27A of the United States
Securities Act of 1933, as amended) concerning PDS Biotechnology
Corporation (the “Company”) and other matters. These statements may
discuss goals, intentions and expectations as to future plans,
trends, events, results of operations or financial condition, or
otherwise, based on current beliefs of the Company’s management, as
well as assumptions made by, and information currently available
to, management. Forward-looking statements generally include
statements that are predictive in nature and depend upon or refer
to future events or conditions, and include words such as “may,”
“will,” “should,” “would,” “expect,” “anticipate,” “plan,”
“likely,” “believe,” “estimate,” “project,” “intend,” “forecast,”
“guidance”, “outlook” and other similar expressions among others.
Forward-looking statements are based on current beliefs and
assumptions that are subject to risks and uncertainties and are not
guarantees of future performance. Actual results could differ
materially from those contained in any forward-looking statement as
a result of various factors, including, without limitation: the
Company’s ability to protect its intellectual property rights; the
Company’s anticipated capital requirements, including the Company’s
anticipated cash runway and the Company’s current expectations
regarding its plans for future equity financings; the Company’s
dependence on additional financing to fund its operations and
complete the development and commercialization of its product
candidates, and the risks that raising such additional capital may
restrict the Company’s operations or require the Company to
relinquish rights to the Company’s technologies or product
candidates; the Company’s limited operating history in the
Company’s current line of business, which makes it difficult to
evaluate the Company’s prospects, the Company’s business plan or
the likelihood of the Company’s successful implementation of such
business plan; the timing for the Company or its partners to
initiate the planned clinical trials for PDS0101, PDS0203 and other
Versamune® and Infectimune® based product candidates; the future
success of such trials; the successful implementation of the
Company’s research and development programs and collaborations,
including any collaboration studies concerning PDS0101, PDS0203 and
other Versamune® and Infectimune® based product candidates and the
Company’s interpretation of the results and findings of such
programs and collaborations and whether such results are sufficient
to support the future success of the Company’s product candidates;
the success, timing and cost of the Company’s ongoing clinical
trials and anticipated clinical trials for the Company’s current
product candidates, including statements regarding the timing of
initiation, pace of enrollment and completion of the trials
(including the Company’s ability to fully fund its disclosed
clinical trials, which assumes no material changes to the Company’s
currently projected expenses), futility analyses, presentations at
conferences and data reported in an abstract, and receipt of
interim or preliminary results (including, without limitation, any
preclinical results or data), which are not necessarily indicative
of the final results of the Company’s ongoing clinical trials; the
Company’s ability to continue as a going concern; any Company
statements about its understanding of product candidates mechanisms
of action and interpretation of preclinical and early clinical
results from its clinical development programs and any
collaboration studies; and other factors, including legislative,
regulatory, political and economic developments not within the
Company’s control. The foregoing review of important factors that
could cause actual events to differ from expectations should not be
construed as exhaustive and should be read in conjunction with
statements that are included herein and elsewhere, including the
other risks, uncertainties, and other factors described under “Risk
Factors,” “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” and elsewhere in the documents
we file with the U.S. Securities and Exchange Commission. The
forward-looking statements are made only as of the date of this
press release and, except as required by applicable law, the
Company undertakes no obligation to revise or update any
forward-looking statement, or to make any other forward-looking
statements, whether as a result of new information, future events
or otherwise.
Versamune® and Infectimune® are registered
trademarks of PDS Biotechnology Corporation. KEYTRUDA® is a
registered trademark of Merck Sharp and Dohme LLC, a subsidiary of
Merck & Co., Inc., Rahway, N.J., USA.Investor
Contact:Rich CockrellCG CapitalPhone: +1 (404)
736-3838Email: pdsb@cg.capital
Media Contact:Gina Cestari6 DegreesPhone: +1
(917) 797-7904Email: gcestari@6degreespr.com
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Apr 2024 to May 2024
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From May 2023 to May 2024